JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB259132

Human SLC39A1 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

SLC39A1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 3 and Insertion of the selection cassette in exon 3.

View Alternative Names

IRT 1, S39A1_HUMAN, Solute carrier family 39 member 1, ZIP-1, ZIRTL, Zinc transporter ZIP1, Zinc-iron-regulated transporter-like, Zrt- and Irt-like protein 1, hZIP1

2 Images
Sanger Sequencing - Human SLC39A1 knockout HeLa cell lysate (AB259132)
  • Sanger seq

Unknown

Sanger Sequencing - Human SLC39A1 knockout HeLa cell lysate (AB259132)

Allele-2 : Insertion of the selection cassette in exon 3

Sanger Sequencing - Human SLC39A1 knockout HeLa cell lysate (AB259132)
  • Sanger seq

Unknown

Sanger Sequencing - Human SLC39A1 knockout HeLa cell lysate (AB259132)

Allele-1 : 1 bp deletion in exon 3

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 3 and Insertion of the selection cassette in exon 3.

Disease

Adenocarcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab259132-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human SLC39A1 knockout HeLa cell lysate", "number":"AB259132-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB259132-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
SLC39A1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

SLC39A1 also known as ZIP1 is a zinc transporter protein that facilitates the influx of zinc ions into cells. This protein consists of 324 amino acids resulting in a molecular mass of approximately 34.26 kDa. SLC39A1 is expressed in various tissues throughout the body with high levels observed in the prostate pancreas and other zinc-related tissues. The protein belongs to the ZIP family of metal ion transporters which is key in maintaining intracellular zinc homeostasis.
Biological function summary

The SLC39A1 protein plays an essential role in cellular zinc uptake by increasing cytoplasmic zinc concentrations. This protein is not part of a larger complex but interacts with zinc ions directly ensuring adequate zinc availability for numerous cellular processes. Zinc is a critical cofactor for many enzymes and is necessary for proper immune function protein synthesis and cellular proliferation. By regulating zinc levels in cells SLC39A1 supports diverse physiological functions and maintains cellular health.

Pathways

SLC39A1 participates in zinc homeostasis and signal transduction pathways. It is pivotal in the regulation of the metallothionein expression pathway which helps detoxify heavy metals and protect against oxidative stress. Also SLC39A1 interacts with the NF-κB signaling pathway where zinc acts as a second messenger influencing cell survival and immune response. Proteins such as MT (metallothionein) and IκBα interact with SLC39A1 in these pathways thereby linking zinc transport to broader cellular functions and responses.

Disruptions in SLC39A1 function have been linked to prostate cancer and neurodegenerative diseases. In prostate cancer altered zinc transport by SLC39A1 is associated with reduced cellular zinc levels contributing to tumorigenesis. The reduction in zinc affects various proteins involved in prostate cancer progression including the androgen receptor. In neurodegenerative diseases like Alzheimer's dysfunctional zinc homeostasis related to abnormal SLC39A1 activity leads to increased oxidative stress and contributes to neuronal damage. Understanding the role of SLC39A1 in these conditions is important for developing targeted therapeutic strategies.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com